N**********i
发帖数: 161 | | l*******2
发帖数: 1 | 2 季博士今天又买了个新玩具，梅奥医学中心的
Sorrento Secures Exclusive License From Mayo Clinic for Antibody-Drug-
Nanoparticle Albumin-Bound Immune Complex (ADNIC) Platform
September 14, 2020 at 6:00 AM EDT
Download PDF
SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (
Nasdaq: SRNE, "Sorrento") today announced it has entered into an exclusive
license agreement with Mayo Clinic for a potential breakthrough technology
platform that is capable of generating a great diversity of stable antibody-
drug-nanoparticle albumin-bound (nab) immune complexes (ADNICs) targeting
many types of human diseases including various solid and liquid tumors. The
ADNIC is the next generation in antibody drug conjugate (ADC) technology
that potentially addresses limitations of current ADC technology, such as
complex manufacturing processes (e.g., antibody-chemotherapy linkers), which
can affect drug half-life, stability and tumor accessibility, and result in
high cost of goods (COGs). The ADNIC platform is currently generating
clinical data at Mayo Clinic through clinical trials with multiple
investigational products in a variety of cancers including ovarian,
endometrial, and multiple lymphoma sub-types. These trials will continue and
are expected to be expanded.
The ADNIC technology, developed at Mayo Clinic, offers many potential
advantages:
Optimizes the likelihood that a chemotherapeutic payload will be
preferentially delivered to the specific, targeted cancer cell type (
supported by existing preclinical pharmacokinetic (PK) data);
Potentially more efficient and effective than traditional ADCs because
ADNICs allow for the entire ADNIC complex to be absorbed into the targeted
cancer cell rather than just the chemotherapeutic payload; and
Uses non-covalent binding to external albumin sites to potentially
facilitate delivery of both a monoclonal antibody and chemotherapeutic
payload directly to the tumor and its microenvironment.
The ADNIC technology potentially eliminates the need to use covalent linker
technology by incorporating therapeutically or immunologically active
antibodies in a reversible manner with a nanoparticle composed of albumin
and a payload of one or more drugs.
The platform has indicated clinical benefits in an FDA-cleared investigator-
sponsored trial at Mayo Clinic under the supervision of Svetomir Markovic, M
.D., Ph.D., a medical oncologist and hematologist. Preliminary results
suggest that patients have experienced clinical benefit from receiving
prototype product candidates that utilize the ADNIC technology developed by
Dr. Markovic and Wendy Navalo at Mayo Clinic, including objective responses
in heavily pre-treated patients with advanced cancers.
The technology platform is protected by a rich intellectual property
portfolio comprised of 17 patent families, 32 patents granted to date with
life through at least 2035 and another 135 patents pending.
“This stable complex potentially allows for the delivery of higher doses of
active drug directly into the tumor as demonstrated in animal studies and
in preliminary trials in cancer patients,“ according to Dr. Markovic, the
inventor of the ADNIC technology at Mayo Clinic. The reversibility of
complex formation may allow for deeper tumor penetration, thereby
potentially enabling a better anti-tumor effect. The exclusive license to
the ADNIC platform also includes access to a proprietary and scalable
manufacturing process that is expected to enable high product yield and low
COGs.
“The Mayo Clinic-developed ADNIC platform is a perfect fit for our
extensive G-MAB antibody products including but not limited to our anti-PD-
L1, anti-CD38, anti-BCMA and anti-ROR1 antibodies. We will accelerate the
development and commercialization of this amazing technology by generating
and developing multiple next-generation ADNIC product candidates for the
potential treatment of cancer, COVID-19 and other human diseases,” stated
Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics. “Teaming with
Mayo Clinic, this license expands Sorrento’s mission of developing
innovative life-saving medicines for unmet medical needs,” continued Dr. Ji
. Sorrento will continue to execute on the clinical development strategy
developed by Mayo Clinic for multiple ADNIC lead product candidates in COVID
-19 and multiple solid and hematologic malignancies.
Mayo Clinic, Dr. Markovic and Ms. Navalo have financial interests in the
technology referenced in this release. Mayo Clinic will use any revenue it
receives to support its not-for-profit mission in patient care, education
and research.
【在 N**********i 的大作中提到】
: 什么原理？
: 盹盹盹
| x****2
发帖数: 421 | 3 一直跌就没人玩儿了呗。。。。庄家的吃相不能太难看，总要打三巴掌再给颗枣子吃的
lol | w****v
发帖数: 2756 | | w***u
发帖数: 17713 | 5 今天biotech指数涨了6%，鸡脖这么大的beta的涨这么多正常。 | s****a
发帖数: 6521 | 6 狂个p. 老子5块钱买的，18块多的时候没跑。。 |
|
